Viyash Scientific’s Strongest-Ever Quarter, Synergies Beat Targets

Viyash Scientific Limited (Formerly Sequent Scientific Limited) — Q4 FY26 Earnings Call (Quarter & Year ended Mar 31, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly emphasizes record/transformative performance and momentum: “Q4 FY ’26 is the strongest quarter in the company’s history”, “Fiscal year 2026 has been a transformative year”.
• Strong confidence in forward growth and execution: “we are very confident coming years; it’s going to grow very strong”, “we are very confident to maintain these levels” (margins).
• Willingness to discuss growth levers and targets (e.g., 15% growth, synergy ramp), with limited hedging.

2. Key Themes from Management Commentary

• Merger integration delivered and now compounding
• “successful integration of business, operations and corporate functions into one unified strong platform”
• Synergies “tracking pretty well… better than what we anticipated”.
• Profitability step-change + operating leverage
• Q4: “EBITDA surpasses INR200 crores”; FY26 EBITDA up 59.6%.
• Margin expansion attributed to mix optimization and operational efficiency.
• Animal Health is the primary growth engine
• Strong regional growth: “all regions are growing very strong”.
• Strategic shift toward innovator-led life cycle management, plus companion animal platform build (R&D, manufacturing, front-end).
• Manufacturing capacity actions: Spain expansion and Turkey debottlenecking.
• Human Health formulation strategy: move to complex products + internalize APIs
• “changed our strategy… moving into a little more complex products”
• “internalize APIs and also bringing manufacturing into India manufacturing”.
• Dedicated oncology potent lab: “creating dedicated potent lab… for all our new oncology product development”.
• API/CDMO: credibility + approvals pipeline
• Animal health API run-rate improvement: stable ~INR350cr historically → “take it to INR400 crores run rate”.
• CDMO narrative is relationship-driven and longer-cycle; management is “very practical” about timelines.
• Capital allocation + selective inorganic
• With “significant deleveraged balance sheet”, management is “actively evaluating selective inorganic opportunities”.

3. Q&A Analysis

Theme A: CDMO strategy, client base, and revenue contribution

• Core questions
• How CDMO is built: number of clients/products, leads, and expected ramp.
• Whether CDMO could become a larger share of top line (e.g., 30–35%).
• Management response
• CDMO models: (1) innovators on NCE/Phase III → commercial, (2) life cycle management post-patent, (3) specialty companies needing infrastructure.
• Client traction: “at least we work with 8 to 10 innovators”.
• FY27 life cycle management growth expectation: “expecting to grow 40%” on base ~INR200–225cr.
• Specialty/complex products: “did almost 16, 17 products” (timing mostly ‘29–‘30 to ‘35–‘37).
• CDMO share question: management did not commit to 30–35% near-term; emphasized longer ramp and infrastructure build.
• Notable / evasive / strong points
• Strong clarity on models and timelines, but limited quantitative disclosure on total CDMO revenue share beyond “INR200 crores business is currently CDMO” and longer-cycle ramp.
• “I’m very practical on this” + “easy to say CDMO… I don’t want to go into that” signals caution on near-term CDMO scaling.

Theme B: Minority interest / subsidiary accounting

• Core questions
• Which subsidiaries drive minority PAT gap; scale and growth outlook.
• Management response
• U.S. subsidiary (Appco): 60% owned, minority ~40%; revenue ~INR400–425cr.
• Spain subsidiary: 60% owned, revenue ~INR550cr FY26.
• Minority contribution: “about 20% of PAT”.
• Spain buyback option mentioned: “Spain by ’28… option to buy back”.
• Notable
• Direct and specific; no evasion.

Theme C: Animal health portfolio composition, geographies, companion vs companion-distribution partnerships

• Core questions
• What products/geographies targeted; companion health share; companion animal companion vs companion distribution.
• Boehringer Ingelheim (BI) distribution partnership details.
• Management response
• Animal health API: majority innovator-driven; mature products + new API products from ‘28/‘29 onward.
• Companion animal strategic growth: Europe + India; BI partnership started “last quarter”.
• R&D/manufacturing build: “capex clearance for R&D… hiring… manufacturing infrastructure also we are adding this year”.
• Companion animal product development target: “at least we are looking at 7, 8 products per year”.
• Notable
• Strong operational specificity (R&D expansion, product counts), but no explicit companion animal revenue % target in this Q&A section.

Theme D: Gross margin sustainability and margin drivers

• Core questions
• How sustainable gross margins are (55–60% peers) given formulations + API + CDMO mix.
• Whether gross margins will inch up over 3–5 years.
• Management response
• Management argues margins are maintained via forward/backward integration and mix optimization:
  • “maintain those gross margins… confident to maintain”
  • Commodity products ~30–35% gross margin; they “optimize… taking out commodity products”.
• CDMO may improve margins, but current profile is “reasonable”.
• Notable
• Clear framework; however, “plus or minus 1%, 2%” implies limited upside and acknowledges margin ceiling risk.

Theme E: Cash conversion / receivables working capital

• Core questions
• Receivables growth outpacing revenue; next bottleneck; discipline to protect cash conversion.
• Management response
• Receivables increase largely due to revenue growth; days up only “about 5, 6 days”.
• Focus: “convert from EBITDA to net profit” and improve conversion in coming quarters.
• Notable
• Addresses prior investor concern (cash conversion) with a days-based rebuttal.

Theme F: Synergies and cost advantages

• Core questions
• Synergy target (INR60–70cr) vs accrued; additional upside.
• Management response
• Annualized synergy accruing: “close to… INR50 crores, INR60 crores”.
• Total annualized potential: “INR125 crores, INR150 crores… at this point” (annualized) with operational/regulatory timing.
• Notable
• Provides both “tracking” and “hope” numbers; “hoping” language indicates uncertainty.

Theme G: Raw material / freight volatility and geopolitical risk

• Core questions
• Impact of geopolitical issues on raw material availability and price volatility over next 1–2 quarters.
• Management response
• Inventory covers “1 or 2 quarters”.
• Freight/solvent impact limited: “freight impacted… INR1 crores, INR2 crores”.
• Price increases used to balance; “at this point, I don’t see any material impact”.
• Notable
• Hedging on continuation: “if it continues further… next 1 or 2 quarters”.

Theme H: Growth targets (15–20% CAGR) and EBITDA scaling

• Core questions
• Can they sustain 15–20% growth for 5 years; path to EBITDA INR1,000cr and INR1,500cr.
• API growth appears single-digit—why and is it sustainable?
• Management response
• 15% growth: “15% definitely quite possible”.
• EBITDA scaling: INR700cr → INR1,000cr → INR1,500cr; management says INR800cr FY27/28 run-rate achieved earlier; “next 2–3 years” to indicate.
• API single-digit: due to intermediate optimization and timing; expects approvals to drive double-digit next year.
• Notable
• Some targets are not tightly timed (“next session… investor meeting”), and API growth explanation relies on internal mix decisions.

4. Guidance / Outlook

Explicit guidance (quantitative)

• FY27 priorities / targets
• Life cycle management (innovator business) growth: “expecting to grow 40%” (base INR200–225cr).
• Tax rate guidance: “around 27%” average tax rate for FY27/28.
• Growth
• 5-year growth aspiration: “15% definitely quite possible”.
• Synergies
• Annualized synergy tracking: “INR50–60 crores”.
• Potential annualized synergy: “INR125–150 crores” (timing: “next 12 to 18 months”).
• Margin stance
• Management confidence to maintain gross/EBITDA levels; no new numeric EBITDA margin guidance given in this call beyond maintaining current levels.

Implicit signals (qualitative)

• CDMO ramp is longer-cycle: launches “start from maybe ’29 to ’30” and infrastructure build “takes a couple of years”.
• Margin ceiling: gross margin expected to remain “plus or minus 1%, 2%” unless CDMO/CX improvements kick in.
• Investment phase in FY27: “we are going to invest a lot… R&D investments are growing a lot” and some pre-opex for capacity.

5. Standout Statements (direct / revealing)

• “Q4 FY ’26 is the strongest quarter in the company’s history. EBITDA surpasses INR200 crores.”
• “Fiscal year 2026 has been a transformative year… successful integration… into one unified strong platform.”
• “As we enter FY ’27, we are very excited about our product pipeline… sustainable growth road map.”
• Animal health API step-up: “Last 5 years… stable… INR350 crores… The first year… take it to INR400 crores run rate.”
• CDMO practicality: “I’m very practical on this. It’s easy to say CDMO… I don’t want to go into that.”
• Companion animal build intensity: “capex clearance for R&D… hiring… manufacturing infrastructure also we are adding this year”
• Margin ceiling framing: “Even if it improves plus or minus 1%, 2%… these gross margins will be maintained.”
• Cash discipline: “days… within a small range, maybe about 5, 6 days of increase… in control.”
• Growth aspiration: “15% definitely quite possible.”

6. Red Flags / Positive Signals

Red flags
– Limited near-term CDMO quantification: management repeatedly emphasizes longer timelines; analysts asked about CDMO share (30–35%) but management did not confirm.
– Margin upside constrained: gross margin framed as stable with only small improvement range.
– Geopolitical risk not fully dismissed: “if it continues further… next 1 or 2 quarters, we need to see” (raw material/solvent/freight).
– API growth deceleration acknowledged: single-digit growth explained by intermediate optimization and timing—could indicate execution/mix risk.

Positive signals
– Strong profitability turnaround and scale: Q4 PAT turnaround and FY26 EBITDA/PAT surge.
– Clear operational levers: integration, mix optimization, internalization, capacity actions (Spain/Turkey), R&D lab/onco.
– Working capital reassurance using days-based metric.
– Synergy tracking with both “accrued” and “potential” numbers.

7. Historical Comparison & Consistency Analysis (vs prior 3 calls provided)

a. Change in Tone Over Time

• Current call (Q4 FY26): More Optimistic
• Moves from “turnaround / integration” emphasis (earlier) to “record quarter / confidence in sustaining levels”.
• Stronger confidence language: “very confident”, “we are very excited”, “15% definitely”.
• Prior calls
• Aug 2025 (pre-merger): optimism but more about execution and merger “on track”.
• Nov 2025 (merger approved by NCLT): optimistic, but still framed as “new chapter” and integration/synergies.
• Feb 2026 (Q3 FY26 merged entity): confidence in margin sustainability and synergy timing; still more cautious on “synergies not factored”.
• Shift driver
• Now that merger is integrated and FY26 results show major profitability expansion, management is more willing to state growth/margin confidence.

b. Tracking Past Commitments vs Outcomes

• Synergy timing and capture
• Prior (Feb 2026): synergies “mostly takes 18 months-24 months” and not fully factored.
• Current (May 2026): synergies “tracking pretty well… better than anticipated” and annualized INR50–60cr already accruing; potential INR125–150cr in 12–18 months.
• Assessment: ✅ On track / improved vs earlier expectation (management claims better-than-anticipated).
• Margin sustainability
• Prior (Feb 2026): “20%… going to sustain” and synergies not yet fully included.
• Current: gross margin and EBITDA strength maintained; management says “confident to maintain these levels”.
• Assessment: ✅ Delivered / sustained (at least through FY26 and Q4).
• API growth expectations
• Prior (Aug 2025 / May 2025): API momentum toward INR100cr+ run-rate and acceleration with new products.
• Current: API growth in Q4 FY26 is only 5% (API revenue grew 5% YoY to ~INR384cr), and management explains it via intermediate optimization and timing.
• Assessment: ⏳ Delayed / mixed (growth not consistently double-digit in the latest quarter; management attributes to mix/timing rather than demand collapse).

c. Narrative Shifts

• CDMO narrative becomes more “practical/timeline-aware”
• Earlier calls: CDMO described as opportunity with growth potential.
• Current: management emphasizes long-cycle and infrastructure build; “not easy… longer-term perspective”.
• Animal health companion animal becomes the central strategic focus
• Earlier: companion animals discussed as a growth sector; now it’s backed by specific build plans (R&D hiring, manufacturing infrastructure, BI distribution).
• Margin story shifts from “improvement” to “maintenance with limited upside”
• Current: gross margin expected to stay within a narrow band; CDMO may improve but not guaranteed.

d. Consistency & Credibility Signals

• Credibility: Medium–High
• Strength: management consistently ties performance to operational levers (integration, mix, internalization, capacity).
• Weakness: some targets remain qualitative or loosely timed (e.g., EBITDA INR1,000cr/1,500cr path; CDMO share).
• Pattern: when asked for near-term CDMO quantification, management is cautious—this can be credible (realistic) but also limits investor confidence.

e. Evolution of Key Themes

• Demand / market
• Companion animal genericization opportunity emphasized more strongly now (Europe focus, volume growth).
• Margins
• From “margin recovery” (Aug/May 2025) → “sustain 20% EBITDA” (Feb 2026) → “maintain gross margins; small upside” (May 2026).
• Expansion
• From geographic expansion and field force (Aug/Nov 2025) → now includes manufacturing debottlenecking and R&D lab/onco (May 2026).
• Synergies
• From “synergies not yet fully factored” (Feb 2026) → “tracking better than anticipated” (May 2026).

f. Additional Insights (Cross-Period Intelligence)

• Cash conversion remains a recurring investor concern, and management’s response has evolved from general focus to more specific “days in control” framing (May 2026). This suggests the issue is still monitored and not fully resolved.
• API growth deceleration vs earlier “INR100cr run-rate” narrative: management now attributes it to intermediate optimization and timing of approvals—this could be a temporary mix effect, but it also indicates that growth engines are not uniformly ramping.